File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Effective antibiotic regime for postoperative acute cholangitis in biliary atresia - An evolving scene

TitleEffective antibiotic regime for postoperative acute cholangitis in biliary atresia - An evolving scene
Authors
Keywordsantibiotics
Biliary atresia
cholangitis
Issue Date2004
PublisherWB Saunders Co. The Journal's web site is located at http://www.elsevier.com/locate/jpedsurg
Citation
The 37th Annual Meeting of the Pacific Association of Pediatric Surgeons, Seoul, Korea, 16-20 May 2004. In Journal Of Pediatric Surgery, 2004, v. 39 n. 12, p. 1800-1802 How to Cite?
AbstractPurpose: The prompt use of empirical antibiotics is vital in managing post-Kasai cholangitis. The authors published findings of their clinical trial in 1991 and established the use of cefoperazone, with a response rate of 88.9%. Here its clinical use since its introduction is reviewed and the trend in its efficacy is assessed. Methods: A retrospective review was carried out between 1997 and 2003. All episodes of acute cholangitis in patients who underwent Kasai procedure were recorded. Cholangitis was defined as unexplained fever with derangement of liver enzymes. Cefoperazone was started empirically according to the established protocol, and the response to treatment was analyzed. Results: There were 19 patients with a total of 49 episodes of cholangitis. Cefoperazone was used as the first-line empirical antibiotic in 40 of these episodes. Only 30 showed successful response (75%). For the 10 unresponsive episodes, meropenem was used as second-line antibiotic with complete response in all. Conclusions: The efficacy of cefoperazone in the treatment of post-Kasai cholangitis has decreased over the last years. This suggests a need for a more effective first-line empirical antibiotic. From this review, meropenem seems to be a suitable candidate, and a future prospective clinical trial is warranted. © 2004 Elsevier Inc. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/83804
ISSN
2023 Impact Factor: 2.4
2023 SCImago Journal Rankings: 0.949
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorWong, KKYen_HK
dc.contributor.authorFan, AHen_HK
dc.contributor.authorLan, LCLen_HK
dc.contributor.authorLin, SCLen_HK
dc.contributor.authorTam, PKHen_HK
dc.date.accessioned2010-09-06T08:45:25Z-
dc.date.available2010-09-06T08:45:25Z-
dc.date.issued2004en_HK
dc.identifier.citationThe 37th Annual Meeting of the Pacific Association of Pediatric Surgeons, Seoul, Korea, 16-20 May 2004. In Journal Of Pediatric Surgery, 2004, v. 39 n. 12, p. 1800-1802en_HK
dc.identifier.issn0022-3468en_HK
dc.identifier.urihttp://hdl.handle.net/10722/83804-
dc.description.abstractPurpose: The prompt use of empirical antibiotics is vital in managing post-Kasai cholangitis. The authors published findings of their clinical trial in 1991 and established the use of cefoperazone, with a response rate of 88.9%. Here its clinical use since its introduction is reviewed and the trend in its efficacy is assessed. Methods: A retrospective review was carried out between 1997 and 2003. All episodes of acute cholangitis in patients who underwent Kasai procedure were recorded. Cholangitis was defined as unexplained fever with derangement of liver enzymes. Cefoperazone was started empirically according to the established protocol, and the response to treatment was analyzed. Results: There were 19 patients with a total of 49 episodes of cholangitis. Cefoperazone was used as the first-line empirical antibiotic in 40 of these episodes. Only 30 showed successful response (75%). For the 10 unresponsive episodes, meropenem was used as second-line antibiotic with complete response in all. Conclusions: The efficacy of cefoperazone in the treatment of post-Kasai cholangitis has decreased over the last years. This suggests a need for a more effective first-line empirical antibiotic. From this review, meropenem seems to be a suitable candidate, and a future prospective clinical trial is warranted. © 2004 Elsevier Inc. All rights reserved.en_HK
dc.languageengen_HK
dc.publisherWB Saunders Co. The Journal's web site is located at http://www.elsevier.com/locate/jpedsurgen_HK
dc.relation.ispartofJournal of Pediatric Surgeryen_HK
dc.subjectantibioticsen_HK
dc.subjectBiliary atresiaen_HK
dc.subjectcholangitisen_HK
dc.subject.meshAnti-Bacterial Agents - therapeutic use-
dc.subject.meshBiliary Atresia - surgery-
dc.subject.meshCefoperazone - therapeutic use-
dc.subject.meshCholangitis - drug therapy-
dc.subject.meshPostoperative Complications - drug therapy-
dc.titleEffective antibiotic regime for postoperative acute cholangitis in biliary atresia - An evolving sceneen_HK
dc.typeConference_Paperen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0022-3468&volume=39&issue=12&spage=1800&epage=1802&date=2004&atitle=Effective+antibiotic+regime+for+postoperative+acute+cholangitis+in+biliary+atresia+-+an+evolving+sceneen_HK
dc.identifier.emailWong, KKY: kkywong@hkucc.hku.hken_HK
dc.identifier.emailTam, PKH: paultam@hkucc.hku.hken_HK
dc.identifier.authorityWong, KKY=rp01392en_HK
dc.identifier.authorityTam, PKH=rp00060en_HK
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1016/j.jpedsurg.2004.08.027en_HK
dc.identifier.pmid15616934-
dc.identifier.scopuseid_2-s2.0-10944242334en_HK
dc.identifier.hkuros97082en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-10944242334&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume39en_HK
dc.identifier.issue12en_HK
dc.identifier.spage1800en_HK
dc.identifier.epage1802en_HK
dc.identifier.isiWOS:000226162400016-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridWong, KKY=24438686400en_HK
dc.identifier.scopusauthoridFan, AH=7005672891en_HK
dc.identifier.scopusauthoridLan, LCL=7005687228en_HK
dc.identifier.scopusauthoridLin, SCL=8213776500en_HK
dc.identifier.scopusauthoridTam, PKH=7202539421en_HK
dc.customcontrol.immutablesml 161209 - amended-
dc.identifier.issnl0022-3468-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats